The field of oncology is currently undergoing a paradigm shift. Advances in the understanding of tumor biology and in tumor sequencing technology have contributed to the shift towards precision medicine, the therapeutic framework of targeting the individual oncogenic changes each tumor harbors. The success of precision medicine therapies, such as targeted kinase inhibitors and immunotherapies, in other cancers have motivated studies in brain cancers. The high specificity and cost of these therapies also encourage a shift in clinical trial design away from randomized control trials towards smaller, more exclusive early phase clinical trials. While these new trials advance the clinical application of increasingly precise and individualized therapies, their design brings ethical challenges . We review the pertinent ethical considerations for clinical trials of precision medicine in neuro-oncology and discuss methods to protect patients in this new era of trial design.
Petersen KE, Prows CA, Martin LJ, Maglo KN (2014) Personalized medicine, availability, and group disparity: an inquiry into how physicians perceive and rate the elements and barriers of personalized medicine. Public Health Genom 17(4):209–220 CrossRef
Budin-Ljosne I, Harris JR (2015) Ask not what personalized medicine can do for you–ask what you can do for personalized medicine. Public Health Genom 18(3):131–138 CrossRef
Preserving Employee Wellness Programs Act Foxx V, trans. 115th Congress ed2018.
Bombard Y, Bach PB, Offit K (2013) Translating genomics in cancer care. J Natl Compr Cancer Netw 11(11):1343–1353 CrossRef
- Ethical considerations of neuro-oncology trial design in the era of precision medicine
Timothy R. Smith
Marike L. Broekman
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II